STAT+: Lilly wins approval for once-weekly insulin shot
The FDA approved Eli Lilly’s Onswik, a once-weekly basal insulin for adults with type 2 diabetes, offering patients an alternative to daily long-acting insulin injections.
This item is an automated import from an external feed and has not yet been rewritten into a neutral C-IT-ALL summary. Read the full story at the original source below.
Read the full story at STAT News
Related Coverage